SRI International Selects Michael Page As Vice President Of Information Technology Services And Chief Information Officer

MENLO PARK, Calif., Oct. 6, 2014 /PRNewswire/ -- SRI International has appointed Michael Page as vice president of Information Technology Services (ITS) and Chief Information Officer (CIO). In this role, Page will lead SRI's information technology strategy and operations and drive IT-supported business process innovation. He will oversee corporate information systems, network and host security, telecommunications systems, and desktop support services.

"Michael Page's experience is a great fit for SRI's multidisciplinary approach to its client-funded research and innovation activities," said Bill Jeffrey, Ph.D., president and CEO, SRI International. "His collaborative style will be a valuable addition to the SRI leadership team as we build an IT and business process infrastructure that supports increasingly complex work."

Page brings more than 20 years of experience in developing and executing IT strategy to deliver best-in-class systems including ERP, Advanced Planning, PLM, CRM and Business Intelligence. He joins SRI from LSI Corporation (acquired by Avago in 2014). At LSI/Avago, Page served as senior director of business applications, responsible for numerous large-scale business transformation and integration initiatives.

Earlier in his career, he held roles at Dynamic Data Solutions, Tulip International, UK Construction, and General Electric.

Page has a degree in business finance from Liverpool John Moores University and a certificate in accounting from the Association of Chartered Certified Accountants.

About SRI International
SRI International is a nonprofit research and innovation center headquartered in Silicon Valley. Government and business clients worldwide come to SRI for pioneering solutions in biomedical sciences and health, chemistry and materials, computing, education, economic development, energy, security and defense, robotics, sensing, and more. We provide research, laboratory and advisory services, technology development and licenses, deployable systems, products, and venture opportunities. Our innovations have created new industries and marketplace value, and lasting benefits to society. Visit SRI's website and Timeline of Innovation to learn more.

SOURCE SRI International

Suggested Articles

Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million and promising more than €1 billion in biobucks.

In this week's EuroBiotech Report, Gilead and Galapagos ink big deal, Novartis chalks up Alzheimer’s failure and AM-Pharma raises €116 million.

In our EuroBiotech roundup this week, Oryzon posts phase 2 Alzheimer’s data, Mereo eyes fast approval and AC Immune advances Lilly-partnered drug.